Cyxone's presentation at Aktiedagen 27 January now published
Cyxone’s CEO Tara Heitner presented the company at Aktiespararnas Aktiedagen on 27 January 2021. Click here to see the video .Contact Tara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.comAdelgatan 21211 22 Malmö, Sweden About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the